A Phase III Randomized, Open-Label Study of CG1940 and CG8711 Versus Docetaxel and Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer Who Are Chemotherapy-Naïve
A Phase III Randomized, Open-Label Study of CG1940 and CG8711 Versus Docetaxel and Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer Who Are Chemotherapy-Naïve
The purpose of this study is to compare the duration of survival between GVAX® immunotherapy for prostate cancer and chemotherapy treatment in patients with prostate cancer who no longer respond to hormone therapy, who have documented metastases, and who have not been treated with chemotherapy in the past.
Inclusion Criteria:
Exclusion Criteria:
Tuscon, Arizona 85715, United States
Fort Lauderdale, Florida 33308, United States
Miami, Florida 33176, United States
Royal Oak, Michigan 48073-6706, United States
Nantes-Saint Herblain, 44805, France
Homburg/Saar, 66421, Germany